High Platelet Count (Thrombocytosis): Causes and When to Worry

The distinction that organises the whole topic is between reactive (secondary) and clonal (primary) thrombocytosis. In reactive thrombocytosis the bone marrow is healthy and simply receives a signal to produce more platelets. A key role is played by interleukin-6 (IL-6), a cytokine released during inflammation, infection, injury or in the presence of cancer. IL-6 stimulates the liver to produce thrombopoietin, the main hormone driving megakaryocytes, and that translates into a higher platelet count in the blood. It is a physiological response, mechanically similar to the way an infection raises the white cell count.

In clonal thrombocytosis the problem lies in the marrow cells themselves. One mutated stem cell gives rise to a clone of megakaryocytes that produce platelets regardless of the body's needs. The most common mutations driving this process affect three genes: JAK2 (the V617F mutation, present in roughly half of patients with essential thrombocythaemia), CALR (calreticulin, in about one fifth to one quarter) and MPL (the thrombopoietin receptor, in a few). Some patients have none of these three changes (the so-called triple-negative form). This group of diseases includes essential thrombocythaemia (ET), polycythaemia vera and primary myelofibrosis, and together they are called myeloproliferative neoplasms. They are chronic blood cancers, often with a long and relatively mild course, but with a real risk of thrombotic complications.

Why does this distinction matter so much? Because the risk, prognosis and management are entirely different. In reactive thrombocytosis the cause is treated (iron, infection, inflammatory disease) and the platelets normalise on their own. In clonal thrombocytosis we are dealing with a disease that is monitored and treated to reduce the risk of clots. The whole diagnostic process described below therefore comes down to one question: is there a secondary cause that explains the result, and if not, is it necessary to look for a mutation?

How often individual causes occur in practice is shown by a classic clinical analysis from Ulm, Germany. The researchers reviewed the records of all hospital patients who had had a platelet count of 500 G/L or more at least once and divided them into groups by cause.

Two things are worth remembering from this. First, the proportions: even in a hospital population, where high platelets are more common than in the general population, almost 88% of cases had a secondary cause. In a well person with an incidental result at a check-up the distribution is different, but the principle stays the same: reactive causes are looked for first. Second, the clot risk: in secondary thrombocytosis thrombotic events were limited to veins and appeared only where there were other risk factors (for example immobilisation after surgery), whereas in primary thrombocytosis arterial clots were also more frequent.

An important caveat: this study concerns hospitalised patients, mostly with values of 500 G/L or more, and not people with a mildly raised result (450–500 G/L) obtained in an outpatient setting. It also does not translate one to one to the Polish population. We treat it as a good illustration of proportions and of the logic of reasoning, not as exact probabilities for an individual reader.

In textbooks iron deficiency is one of the most frequently listed causes of reactive thrombocytosis, and that is true, but with an important caveat about scale. The phenomenon is clear when the iron deficiency is deep enough to cause anaemia. In a large single-centre data analysis in Boston covering more than 36,000 patients with iron deficiency anaemia, thrombocytosis was found in 32.6%, and the rate of thrombotic events was 7.8% in patients with anaemia alone and 15.8% in patients with anaemia and thrombocytosis. Platelets were higher the lower the haemoglobin.

The picture is different in healthy people with mild iron deficiency. In an analysis of more than 130,000 blood counts and ferritin measurements in about 22,000 healthy blood donors, practically no correlation was found between ferritin concentration and platelet count (correlation coefficients close to zero). The authors noted that this would require further study in patients with more severe anaemia and inflammation. The practical conclusion is therefore cautious: iron deficiency can raise platelets, especially when accompanied by anaemia, but low ferritin alone in a person without anaemia is rarely enough to explain a clearly high platelet count.

How to check this in practice? The simplest route is to measure ferritin together with CRP, because ferritin is an acute-phase protein and during inflammation can be falsely normal despite iron deficiency. Details of interpretation are in our entries on ferritin and CRP. If the identified iron deficiency is corrected and platelets fall within a few weeks, we have retrospective confirmation that the cause was reactive. We also describe separately how atypical red cell indices, such as a low MCV, can point to iron deficiency before haemoglobin falls.

This question reaches the search engine as often as the phrase about causes itself, and it deserves an honest answer, without scaremongering and without downplaying. Thrombocytosis is a known risk marker for cancer, mainly lung and colorectal cancer, but it is a risk marker and not a diagnosis. A large British cohort study based on general practitioners' electronic records followed, for one year, 40,000 patients aged at least 40 with platelets above 400 G/L and 10,000 patients with normal platelets.

How should this be read? The numbers sound worrying, but remember that the study included people for whom a GP had ordered a blood count, that is, usually people who had some reason to be tested. It is not a population of healthy people with an incidental result at a check-up. For someone with high platelets, no symptoms and a younger age, the risk is considerably lower than in a cohort of people over 40 presenting with complaints. On the other hand, the result shows that in a person over forty with persistent thrombocytosis and no obvious cause, a clinical assessment is worth considering: a history of weight loss, blood in the stool, persistent cough, and appropriate imaging or screening tests recommended for that age.

The most sensible conclusion is to keep a sense of proportion: high platelets in an adult over 40, persisting on repeat tests and without an infectious or deficiency cause, are a reason to consult a family doctor, not a reason to panic. The alarm symptoms that change the situation are listed in the red flags section.

Essential thrombocythaemia (ET) is the most common myeloproliferative neoplasm presenting with thrombocytosis. The typical patient is an adult, often middle-aged or older (although the disease also occurs in young women), and platelets can be clearly higher than in an ordinary inflammatory reaction, for example above 600–1000 G/L. This is not a rule, however: the platelet count alone does not distinguish ET from reactive thrombocytosis, and some people with ET have only a slightly raised result.

Diagnosing ET under the World Health Organization criteria requires a combination of several elements: persistently raised platelets (450 G/L or more), a marrow picture showing proliferation of mature megakaryocytes, exclusion of other myeloproliferative neoplasms (polycythaemia vera, myelofibrosis, chronic myeloid leukaemia with BCR-ABL and myelodysplastic syndromes), and the presence of one of the JAK2, CALR or MPL mutations or, in their absence, no reactive cause whatsoever. The diagnosis is made by a haematologist, never from a blood count alone.

Features that increase suspicion of clonal thrombocytosis are: high platelets lasting months with no identified secondary cause, normal inflammatory markers (CRP, ESR), an enlarged spleen, a clot in an unusual site (splanchnic or cerebral veins), episodes of redness and burning of the hands or feet (erythromelalgia), visual disturbances or vascular-type headaches, and parallel abnormalities in other parameters, for example a raised haematocrit or leucocytosis. None of these features settles the matter alone, but together they form a picture that justifies referral to a haematologist.

Why does the diagnosis matter if ET often runs a mild course? Because of the risk of thrombotic and, less often, haemorrhagic complications. Treatment strategy depends on risk assessment (age, previous clot, cardiovascular risk factors, JAK2 mutation) and ranges from observation alone and low-dose acetylsalicylic acid to cytoreductive drugs. These decisions are made by a haematologist, not by a patient on the basis of reading an article, so we do not encourage taking aspirin on your own because of a blood count result alone.

This sequence matches the logic of the British haematology society guideline on managing thrombocytosis in adults and children, which recommends first excluding reactive causes and reserving molecular testing for cases in which no secondary cause is found. A diagnostic review from the Mayo Clinic team describes the same principle: first check whether the thrombocytosis is spurious (an artefact), reactive or clonal. It is worth remembering that falsely raised results also occur occasionally, for example when the analyser counts fragments of red or white cells as platelets, which is why repeating the test and looking at the smear make sense.

Pregnancy and the postpartum period are a separate situation. In pregnancy platelets usually fall slightly, and after delivery, especially with blood loss, they may rise temporarily. A woman of childbearing age with diagnosed ET needs pregnancy planning under haematological care, but that is a topic for a separate consultation, not for independent conclusions from a blood count result.

If high platelets were found incidentally, you feel well and follow-up tests show a falling trend, the care of a family doctor is usually enough. If, however, the platelet count is rising or persists unexplained for several weeks, or one of the symptoms above appears, the next step should be haematology, not further guessing on your own. A visit to a haematologist does not mean a diagnosis of cancer. Its purpose is precisely to settle whether one is present at all.

The question also arises whether supplements and diet can 'lower platelets'. There is no reliable evidence that any supplement effectively and safely lowers the platelet count in clonal thrombocytosis. In reactive thrombocytosis it is treating the cause that lowers it. Importantly, iron supplementation in confirmed deficiency is treatment of the cause and platelets usually fall afterwards, but starting it without measuring ferritin is risky, because excess iron is harmful and the ferritin result is key to the right decision.

High platelets are a result that easily causes anxiety, yet also one of those in which calm, orderly diagnostics give the best outcome. Data from large analyses show that most cases have a secondary cause that can be found with two inexpensive tests (CRP and ferritin), while the share of patients with a primary marrow disease is clearly smaller. At the same time, a result that persists unexplained cannot be ignored, especially after the age of 40 or with thrombotic symptoms. The sensible path is to repeat the test, consider the context, run simple tests and, if there is no explanation, see a haematologist. In our series on unusual blood count results we also cover low platelets, high eosinophils, low white cells and high MCV separately, because each of these patterns has its own diagnostic logic.